ClinicalTrials.gg
CompletedNCT06692322Updated Nov 2, 2026Results posted

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

A Phase 1 interventional study of Zongertinib in Liver Diseases and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Updated Nov 2, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
169th of 269
29 · median 48
Started
2025
with 9 others
Phase 1
62 of 368
4 open now
Registered
349th of 368
by date
Lead sponsor
5 of 368
Boehringer Ingelheim

Among the 368 studies in Liver Diseases with a site in United States, this one is the 169th largest by enrollment of the 269 interventional ones that give a count, is one of 10 that started in 2025, is one of 62 in phase 1, and was the 349th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m\^2 can take part. Women can only participate if they cannot get pregnant. This study includes people with mild liver problems, people with moderate liver problems, and people without liver problems as a matching control. The purpose of this study is to find out how mild and moderate liver problems affect how the body handles a medicine called zongertinib.

Participants take zongertinib once as tablets. Participants with liver problems are treated in a step-by-step approach with a few days in between for the doctors to review the data and make sure the participants can tolerate the treatment. Participants may continue their regular treatment for their liver problems during the study.

Participants are in the study for about 5 weeks. During this time, they visit the study site 4 times. This also includes an overnight stay for 6 nights. During study visits, the doctors regularly check participants' health and take note of any unwanted effects. To assess the study endpoints, the study staff regularly takes blood samples.

03

Conditions studied

  • Liver Diseases
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects of non-. Female subjects must be of non-childbearing potential either be a) , defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of Follicle stimulating hormone (FSH) above 25 U/L and estradiol below 30 ng/L is confirmatory) or b) have proof of acceptable surgical sterilization. Subjects must use condom from time point of administration of trial medication until 30 days after drug administration.
  • Age of 18 to 80 years (inclusive)
  • (BMI) of 18.0 to 42 kg/m\^2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Male subjects with Women of child-bearing potential (WOCBP) partner must be willing to use highly effective methods of (condom in combination with other methods or sexual abstinence) from time point of administration of trial medication until 30 days thereafter. These include:

    • Subject uses condoms
    • Subject is sexually abstinent
    • Subject is vasectomized (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate) and uses condom

Additionally female partners of male subjects must be willing to use any of the following criteria for a highly effective contraception from at least 30 days before the first administration of the male partner until 30 days thereafter:

  • Use of intrauterine device or intrauterine hormone-releasing system by female partner plus use of condom
  • Use of progestogen-only hormonal contraception by female partner that inhibits ovulation (injectables or implants) plus use of condom
  • Use of combined (estrogen and progestogen containing) hormonal contraception by female partner that prevents ovulation (oral, intravaginal, or transdermal) plus use of condom
  • Surgically sterilised (including hysterectomy or bilateral tubular occlusion) plus use of condom
  • Postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of FSH above 25 U/L and estradiol below 30 ng/L is confirmatory) plus use of condom

    • For group 1 and 2 only: Hepatic impairment classified as A (score 5-6 points) or Child-Pugh B (score 7-9 points)
    • For group 1 and 2 only: Absence of abnormalities, as based on a complete medical history including a full physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12- lead (ECG), and clinical laboratory tests at both screening and admission to trial site, with the exception of findings that in the opinion of the investigator are consistent with the participant's hepatic impairment
    • For group 1 and 2 only: Medication and/or treatment regimens must have been stable (i.e., no dose adjustments) for at least 4 weeks prior to the screening period and should be kept stable until study completion Fluctuating treatment regimens may be considered for inclusion on a case-by-case basis if the underlying disease is under control in the opinion of the investigator and must be agreed to by both the investigator and the sponsor's medical monitor Further inclusion criteria apply.

Exclusion criteria

exclusion criteria

  • Any finding in the medical examination (including BP, PR or ) assessed as by the investigator (apart from any non-severe hepatic impairment and associated underlying diseases)
  • Severe hepatic impairment (classified as C or score 10-15)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance (apart from values due to underlying disease)
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator (apart from underlying disease)
  • Severe gastrointestinal, renal (Estimated (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \<40 ml/min/1.73 m2 for the hepatic impaired patients and eGFR CKD-EPI \<90 ml/min/1.73 m2 for matched controls), respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the Investigator.
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, repetitive fainting spells, or repetitive blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Child-Pugh A

    This arm comprised participants with mild hepatic impairment classified as Child-Pugh A, who received a single oral dose of 120 mg of zongertinib with 240 mL of water, following an overnight fast of at least 10 hrs.

    Drug: Zongertinib

  • Experimental
    Child-Pugh B

    This arm comprised participants with moderate hepatic impairment classified as Child-Pugh B, who received a single oral dose of 120 mg of zongertinib with 240 mL of water, following an overnight fast of at least 10 hrs.

    Drug: Zongertinib

  • Experimental
    Matched control

    This arm comprised all participants with normal hepatic function, individually matched to participants with hepatic impairment according to age, sex, and weight, and who received a single oral dose of 120 milligrams (mg) of zongertinib with 240 milliliters (mL) of water, following an overnight fast of at least 10 hrs.

    Drug: Zongertinib

Interventions

  • Participants received a single oral dose of 120 milligrams (mg) of zongertinib with 240 milliliters (mL) of water, following an overnight fast of at least 10 hrs

    Also known as: BI 1810631, Hernexeos®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞ (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.

  2. Maximum Measured Concentration of Zongertinib in Plasma (Cmax)

    Cmax (maximum measured concentration of zongertinib in plasma) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    AUC0-tz (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

    Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.

07

Results

Posted Nov 2, 2026

Participant flow

This was a non-randomised, open-label, parallel, individual-matched trial to investigate the effect of mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics (PK) of zongertinib.

Participant flow — Overall Study
MilestoneMatched ControlChild-Pugh AChild-Pugh B
Started1388
Completed1388
Not completed000

Outcome measures

PrimaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞ (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hours*nanomoles/Liter (h*nmol/L)Child-Pugh AMatched Control to Child-Pugh AChild-Pugh BMatched Control to Child-Pugh B
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)31457.80 (26367.83 to 37530.15)28490.38 (23880.08 to 33989.26)20568.79 (16708.95 to 25318.74)24689.75 (20058.33 to 30390.95)
Statistical analysis
  • Child-Pugh A vs Matched Control to Child-Pugh A · Ratio of adjusted geometric means (Child · Ratio of adjusted geometric means (t/r): 110.42 · 90% CI 86.03 to 141.72Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 26.8%
  • Child-Pugh B vs Matched Control to Child-Pugh B · Ratio of adjusted geometric means (t/r): 83.31 · 90% CI 62.10 to 111.77Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 31.8%
PrimaryMaximum Measured Concentration of Zongertinib in Plasma (Cmax)

Cmax (maximum measured concentration of zongertinib in plasma) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Reported as:
Geometric least squares mean · nanomoles/Liter (nmol/L)
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)
nanomoles/Liter (nmol/L)Child-Pugh AMatched Control to Child-Pugh AChild-Pugh BMatched Control to Child-Pugh B
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)2335.43 (1992.21 to 2737.77)2397.44 (2045.10 to 2810.45)1322.88 (1077.50 to 1624.09)2035.46 (1658.05 to 2498.89)
Statistical analysis
  • Child-Pugh A vs Matched Control to Child-Pugh A · Ratio of adjusted geometric means (Child · Ratio of adjusted geometric means (t/r): 97.41 · 90% CI 77.80 to 121.97Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 24.1%
  • Child-Pugh B vs Matched Control to Child-Pugh B · Ratio of adjusted geometric means (t/r): 64.99 · 90% CI 48.63 to 86.86Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 31.4%
SecondaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

AUC0-tz (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.

Time frame:
Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Reported as:
Geometric least squares mean · hours*nanomoles/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hours*nanomoles/Liter (h*nmol/L)Child-Pugh AMatched Control to Child-Pugh AChild-Pugh BMatched Control to Child-Pugh B
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)30858.52 (25729.67 to 37008.39)27905.66 (23267.20 to 33469.84)19956.22 (16097.19 to 24740.58)23995.72 (19354.88 to 29747.49)
Statistical analysis
  • Child-Pugh A vs Matched Control to Child-Pugh A · Ratio of adjusted geometric means (Child · Ratio of adjusted geometric means (t/r): 110.58 · 90% CI 85.51 to 143.00Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 27.6%
  • Child-Pugh B vs Matched Control to Child-Pugh B · Ratio of adjusted geometric means (t/r): 83.17 · 90% CI 61.37 to 112.71Ratio as percentage \[%\] Intra-matched pair geometric coefficient of variation (gCV) = 32.9%

Adverse events

Collected over Serious Adverse Events and Other Adverse Events: From study drug administration until end of the residual effect period (i.e. 14 days), up to 336 hours. All-cause mortality: From drug administration till end of trial, up to 18 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Matched Control0/13 (0%)0/13 (0%)1/13 (7.7%)
Child-Pugh A0/8 (0%)0/8 (0%)0/8 (0%)
Child-Pugh B0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventMatched ControlChild-Pugh AChild-Pugh B
DiarrhoeaGastrointestinal disorders1/130/81/8

Baseline characteristics

Treated set (TS): The treated set included all participants who were treated with at least 1 dose of trial drug. One subject with normal hepatic function could be matched with one subject in one or both groups with hepatic impairment.

Age, Continuous
Age, Continuous(Years)Matched ControlChild-Pugh AChild-Pugh BTotal
Mean58.6 ± 6.362.0 ± 5.958.9 ± 4.459.6 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)Matched ControlChild-Pugh AChild-Pugh BTotal
Female4318
Male95721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Matched ControlChild-Pugh AChild-Pugh BTotal
Hispanic or Latino67720
Not Hispanic or Latino7119
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Matched ControlChild-Pugh AChild-Pugh BTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White128828
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2025, 5 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 18, 2024
StartActual
Jan 15, 2025
Primary completionActual
Jun 20, 2025
CompletionActual
Jun 20, 2025
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 2, 2026
Interventions
Changed Zongertinib (BI 1810631)→Zongertinib. Arm changed Mild hepatic impairment (Child-Pugh A)→Child-Pugh A; Moderate hepatic impairment (Child-Pugh B)→Child-Pugh B. Arms added: Matched control; arms removed: Normal hepatic function
Nov 2, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteZongertinib in plasma overPlasma Over the time interval fromTime Interval From 0 Extrapolated to infinityInfinity (AUC0-∞)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
  • EditedMaximum measured concentrationMeasured Concentration of the analyteZongertinib in plasmaPlasma (Cmax)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Nov 2, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteZongertinib in plasma overPlasma Over the time interval fromTime Interval From 0 to the last quantifiable data pointLast Quantifiable Data Point (AUC0-tz)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteZongertinib in plasma overPlasma Over the time interval fromTime Interval From 0 Extrapolated to infinityInfinity (AUC0-∞)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
    • EditedMaximum measured concentrationMeasured Concentration of the analyteZongertinib in plasmaPlasma (Cmax)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteZongertinib in plasma overPlasma Over the time interval fromTime Interval From 0 to the last quantifiable data pointLast Quantifiable Data Point (AUC0-tz)Time frame: up to 8 days → Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
    Interventions Changed Zongertinib (BI 1810631)→Zongertinib. Arm changed Mild hepatic impairment (Child-Pugh A)→Child-Pugh A; Moderate hepatic impairment (Child-Pugh B)→Child-Pugh B. Arms added: Matched control; arms removed: Normal hepatic function
    + 5 other changes: verification date, references, data sharing statement, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06692322
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Jan 15, 2025
Primary completion
Jun 20, 2025
Completion
Jun 20, 2025
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion